{"id":170582,"date":"2025-08-25T07:45:19","date_gmt":"2025-08-25T11:45:19","guid":{"rendered":"https:\/\/44.250.171.167\/?p=170582"},"modified":"2025-08-25T13:29:15","modified_gmt":"2025-08-25T17:29:15","slug":"alkem-laboratories-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q1-fy26-earnings-results\/","title":{"rendered":"Alkem Laboratories Q1 FY26 Earnings Results"},"content":{"rendered":"<p>Alkem Laboratories Ltd is a global pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Presenting below its Q1 FY26 Earnings Results.<\/p>\n<h2><strong>Q1 FY26 Earnings Results<\/strong><\/h2>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b93,371 crore, up 11.18% year-on-year (YoY) from \u20b93,032 crore in Q1 FY25.<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b92,750 crore, up 8.61% YoY from \u20b92,532 crore.<\/li>\n<li><strong>Consolidated Net Profit (PAT):<\/strong> \u20b9668 crore, up 21.45% from \u20b9550 crore in the same quarter last year.<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b955.56, up 21.84% from \u20b945.60 YoY.<\/li>\n<\/ul>\n<h2><strong>Operational &amp; Strategic Update<\/strong><\/h2>\n<ul>\n<li><strong>Revenue Growth:<\/strong> Revenues increased by over 11%, driven by strong demand across pharmaceutical and nutraceutical segments globally.<\/li>\n<li><strong>Expense Management:<\/strong> Expenses rose by 8.61%, lower than revenue growth, supporting margin expansion.<\/li>\n<li><strong><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/ea91a609-60ad-46b1-8ed3-a996c6833f70.pdf\" target=\"_blank\" rel=\"noopener\">Profit Surge<\/a><\/strong><strong>:<\/strong> Net profit and EPS grew by over 21%, showing strong operational leverage and enhanced profitability.<\/li>\n<li><strong>Market Position:<\/strong> Alkem Laboratories maintains a robust presence in the pharmaceutical industry with a diversified product portfolio and global market reach.<\/li>\n<li><strong>Strategic Focus:<\/strong> The company is focused on innovation, portfolio expansion, and scaling operations across domestic and international markets.<\/li>\n<\/ul>\n<h2><strong>Corporate Developments in Q1 FY26 Earnings<\/strong><\/h2>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/ea91a609-60ad-46b1-8ed3-a996c6833f70.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> results underline Alkem Laboratories\u2019 solid profit growth supported by revenue expansion and effective cost control.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-170583\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png\" alt=\"ALKEM Q1 FY26 Earnings Results\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<h2><strong>Looking Ahead<\/strong><\/h2>\n<p>Alkem Laboratories Ltd aims to continue growth through new product launches, increased global penetration, and operational efficiency. The company is positioned to sustain value creation through FY26 and beyond.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts,<a href=\"https:\/\/44.250.171.167\/symbol\/alkem\/\"> click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alkem Laboratories Ltd is a global pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b93,371 crore, up 11.18% year-on-year (YoY) from \u20b93,032 crore in Q1 FY25. Total Expenses: \u20b92,750 crore, up 8.61% YoY from \u20b92,532 crore. Consolidated [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":170583,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-170582","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":172398,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q2-fy26-earnings-results\/","url_meta":{"origin":170582,"position":0},"title":"Alkem Laboratories Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 14, 2025","format":false,"excerpt":"Alkem Laboratories, engaged in the pharmaceutical and nutraceutical business with global operations, reported steady financial results for Q2FY26. Financial Highlights: Revenues increased 17.16% year-on-year to \u20b94,001 crore from \u20b93,415 crore. Total expenses rose 15.89% to \u20b93,209 crore from \u20b92,769 crore. Consolidated net profit grew 10.97% to \u20b9779 crore from \u20b9702\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170171,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":170582,"position":1},"title":"Divi&#8217;s Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 14, 2025","format":false,"excerpt":"Divi\u2019s Laboratories Limited, incorporated in 1990, is engaged in the manufacture and export of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceutical ingredients. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b92,410 crore, up 13.79% year-on-year (YoY) from \u20b92,118 crore in Q1 FY25. Total Expenses: \u20b91,796\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"DIVISLAB Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170965,"url":"https:\/\/alphastreet.com\/india\/caplin-point-q1-fy26-earnings-results\/","url_meta":{"origin":170582,"position":2},"title":"Caplin Point Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 5, 2025","format":false,"excerpt":"Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of active pharmaceutical ingredients APIs, finished formulations, research and development, and clinical research. The company has a strong international footprint with significant presence in Latin America, Africa, the USA, and other key markets. Q1 FY26 Earnings Summary Revenue: \u20b9510\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"CAPLIPOINT Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170341,"url":"https:\/\/alphastreet.com\/india\/unichem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":170582,"position":3},"title":"Unichem Laboratories Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 19, 2025","format":false,"excerpt":"Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. The company operates 3 formulation facilities at Goa, Baddi, and Ghaziabad, and 3 API facilities at Roha, Pithampur, and Kolhapur. The company has initiated backward integration and upscaling for 6-8 major captive APIs. At the\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Unichem Laboratories Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":170582,"position":4},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170447,"url":"https:\/\/alphastreet.com\/india\/aarti-drugs-q1-fy26-earnings-results\/","url_meta":{"origin":170582,"position":5},"title":"Aarti Drugs Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 21, 2025","format":false,"excerpt":"Aarti Drugs Ltd, established in 1984 and part of the $1000 million Aarti Group of Industries, is engaged in manufacturing and selling Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals, as well as pharmaceutical formulations. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9591 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AARTIDRUGS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=170582"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170582\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/170583"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=170582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=170582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=170582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}